Oragenics, Inc. (NYSEAMERICAN:OGEN) was the recipient of a large decline in short interest in August. As of August 31st, there was short interest totalling 2,130,000 shares, a decline of 41.3% from the August 15th total of 3,630,000 shares. Based on an average daily volume of 5,910,000 shares, the short-interest ratio is presently 0.4 days. Approximately 1.9% of the company’s shares are short sold.
Shares of OGEN traded down $0.02 during trading hours on Friday, reaching $0.64. 914,244 shares of the company traded hands, compared to its average volume of 11,764,723. The firm has a fifty day moving average price of $0.45. The stock has a market cap of $74.02 million, a P/E ratio of -3.03 and a beta of 0.19. Oragenics has a 12 month low of $0.38 and a 12 month high of $1.80.
Oragenics (NYSEAMERICAN:OGEN) last announced its earnings results on Monday, August 16th. The biotechnology company reported ($0.03) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.01.
Oragenics Company Profile
Oragenics, Inc develops antibiotics for infectious diseases in the United States. Its lead product candidate under development is OG716, an antibiotic for the treatment of Clostridium difficile. The company also engages in the development and commercialization of Terra CoV-2, a vaccine product candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.
See Also: Call Option
Receive News & Ratings for Oragenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oragenics and related companies with MarketBeat.com's FREE daily email newsletter.